Evidence map›Paper›PMID 35629144›Full record

ArticleJournal of personalized medicine2022

Modified Geometry of

Héctor Miras, José Antonio Terrón, Alejandro Bertolet, Antonio Leal

Abstract read
In one paragraph

Article in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Héctor MirasDepartment of Medical Physics, Hospital Universitario Virgen Macarena, E-41009 Seville, Spain.ORCID 0000-0002-0534-3657
José Antonio TerrónDepartment of Medical Physics, Hospital Universitario Virgen Macarena, E-41009 Seville, Spain.ORCID 0000-0001-5123-9597
Alejandro BertoletDepartment of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0002-9890-693X
Antonio LealInstituto de Biomedicina de Sevilla, IBIS, E-41013 Seville, Spain.ORCID 0000-0002-0687-5305

Funding

Radiation dosimetry for alpha-particle radiopharmaceutical therapy and application to pediatric neuroblastomaK99CA267560 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BERTOLET REINA, ALEJANDRO · 2022 to 2023
$188k
NCI NIH HHS K99 CA267560
6 · The paper itself

Abstract

Ru/Rh asymmetric plaques for ophthalmic brachytherapy have special geometric designs with a cutout intended to prevent irradiation of critical ocular structures proximal to the tumor. In this work, we present new geometric models for PENELOPE+PenEasy Monte Carlo simulations of these applicators, differing from the vendor-reported geometry, that better match their real geometry to assess their dosimetric impact. Simulation results were benchmarked to experimental dosimetric data from radiochromic film measurements, data provided by the manufacturer in the calibration certificates, and other experimental results published in the literature, obtaining, in all cases, better agreement with the modified geometries. The clinical impact of the new geometric models was evaluated by simulating real clinical cases using patient-specific eye models. The cases calculated using the modified geometries presented higher doses to the critical structures proximal to the cutout region. The modified geometric models presented in this work provide a more accurate representation of the asymmetric plaques, greatly improving the agreement between Monte Carlo calculations and experimental measurements. Lack of consideration of accurate geometric models has been shown to be translated into notable increases in dose to organs at risk in clinical cases.

Indexed as

Monte Carloophthalmic brachytherapyruthenium plaque

Identifiers

PMID35629144
PMCPMC9144752

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.